Bank Of America Corp Syndax Pharmaceuticals Inc Transaction History

Bank Of America Corp

$1.06 Trillion
Q1 2024

A detailed history of Bank Of America Corp transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Bank Of America Corp holds 1,655,052 shares of SNDX stock, worth $31.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,655,052

Previous 984,258 68.15%

Holding current value

$31.9 Million

Previous $21.3 Million 85.2%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$19.71 - $24.57 $13.2 Million - $16.5 Million	670,794 Added 68.15%	1,655,052 $39.4 Million
Q4 2023 Feb 14, 2024	BUY	$11.39 - $21.67 $7.98 Million - $15.2 Million	700,391 Added 246.73%	984,258 $21.3 Million
Q2 2023 Aug 14, 2023	SELL	$19.35 - $22.31 $2.15 Million - $2.48 Million	-111,302 Reduced 28.17%	283,867 $5.94 Million
Q1 2023 May 12, 2023	BUY	$20.66 - $28.98 $2.63 Million - $3.69 Million	127,457 Added 47.61%	395,169 $8.35 Million
Q4 2022 Feb 10, 2023	SELL	$20.64 - $26.24 $710,346 - $903,075	-34,416 Reduced 11.39%	267,712 $6.81 Million

Q3 2022 Nov 14, 2022	BUY	$18.51 - $24.79 $4.19 Million - $5.61 Million	226,494 Added 299.46%	302,128 $7.26 Million
Q2 2022 Aug 12, 2022	SELL	$13.64 - $19.48 $518,606 - $740,649	-38,021 Reduced 33.45%	75,634 $1.46 Million
Q1 2022 May 16, 2022	SELL	$14.84 - $22.15 $1.12 Million - $1.67 Million	-75,282 Reduced 39.85%	113,655 $1.98 Million
Q4 2021 Feb 08, 2022	BUY	$15.23 - $22.47 $1.5 Million - $2.22 Million	98,760 Added 109.52%	188,937 $4.14 Million
Q3 2021 Nov 15, 2021	BUY	$13.87 - $19.8 $795,305 - $1.14 Million	57,340 Added 174.62%	90,177 $1.72 Million
Q2 2021 Sep 13, 2021	BUY	$13.42 - $25.18 $440,672 - $826,835	32,837 New	32,837 $564,000

Others Institutions Holding SNDX

# of Institutions

195

Shares Held

90M

Call Options Held

353K

Put Options Held

207K

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $1.09B
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Syndax Pharmaceuticals Inc Transaction History